Healthcare >> Sector Roundtables >> April 28, 2003

Roundtable Forum: Canadian Biotechnology

KELLY HOLMAN is a Founder and Managing Director of Genesys Capital and has extensive commercial and technical experience in the biotechnology industry. Since co-founding Genesys Capital Partners in 2000, he has been actively involved in assisting the Triax-Covington NewGen Funds raise over $100 million of venture capital and has been instrumental in deploying over $60 million across 16 investments. He serves on the Board of Directors of Affinium Pharmaceuticals Inc., Epocal Inc., matRegen Corp. and Interface Biologics Inc. He is active in deal origination and company creation and has advised Canada's National Biotechnology Advisory Committee on strategies for financing startup and early-stage biotechnology companies. He holds a Bachelor of Science (honors) in Biochemistry and an MBA, both from Queen's University. Profile
CLAUDE CAMIR has had a 20-year career covering the pharmaceutical, biotech and medical devices industries, including the last four years as a healthcare analyst. His coverage of the sector includes biotech, service and manufacturing companies in Canada and the US. He has worked in senior and managerial positions covering marketing, finance and business development activities for Abbott Laboratories, Aventis (Rhone- Poulenc Rorer) and Biochem Pharma. He has been involved extensively in technology valuation, financing and mergers and acquisitions in North America and Europe. He has received his B. Comm (Finance/Accounting) degree from the University of Sherbrooke. He is currently enrolled in the MBA program at the Universit_ du Qu_bec in Montreal and the CFA program level 2 (exam scheduled for June 2003). Profile
TWST: Kelly, is there a differentiation between the Canadian and US

markets in biotech?

Mr. Holman: From the buyside perspective, there certainly is. It's

really a function of the maturity of